Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.

NCT02097849 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02097849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02097849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
May 2, 2016
Enrollment
71 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing forms of multiple sclerosis